ClinicalTrials.gg

Program

JNJ-88545223

A development code.

Its studies are mostly in Arthritis, Psoriatic, led by Johnson & Johnson.

Furthest: phase 2, since Jan 5, 20261 company-led study, 1 open or runningNext primary completion: Jun 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 2since Jan 5, 2026Jan 5, 2026Jun 28, 2027phase 2 · NCT07321873

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 5, 2026First study: phase 2 study in Arthritis, PsoriaticFirst studyNCT07321873 · 157 enrolled · United States, China, Czechia and more

Ahead

  1. Jun 28, 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07321873

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07321873Arthritis, Psoriatic · United States, China, Czechia and more2Active, not recruitingJun 28, 2027157

How it is read

Names in the registry

  • “JNJ-88545223”, 1 entry

Codes read as this program: JNJ88545223.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.